2019 Edogawa NICHE Prize Awarded to Dr. Steven Rosenberg for His Pioneering Feat in Tackling Cancer with Immunotherapy
15.8.2019 09:00:00 EEST | Business Wire | Press release
The Edogawa NICHE Committee today announced that the 2019-Edogawa NICHE Prize (www.edogawanicheprize.org) has been awarded to Dr. Steven A. Rosenberg, for his pioneering work in developing effective adoptive immunotherapies and genetically modified T cells which has heralded the birth of a new chapter in the fight against cancer. Dr. Rosenberg’s accomplishment has significantly contributed to the development of several immune system-based drugs and clinically effective immunotherapies including the CAR-T cell therapy.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190814005237/en/
Dr. Steven A. Rosenberg, 2019 Edogawa NICHE Prize Awardee (Photo: Business Wire)
Dr. Rosenberg is an epitome of significance of inter-disciplinary interaction in developing clinical solutions, who after his Medical degree at Johns Hopkins University, obtained doctorate in Biophysics. Now leads a strong interdisciplinary team devoted to find novel solutions to cancer, as the Chief, Surgery Branch at the National Cancer Institute (NCI), MD, USA and as Professor of Surgery at the Uniformed Services University of Health Sciences and the George Washington University School of Medicine and Health Science.
Instead of two or more specialists’ interaction, making the inter-disciplinary interaction meaningful, we found one passionate scholar in Dr. Rosenberg, walking through the portals of different domains of science by himself, opening a new path to solve an age-old problem is considered worth that this award be bestowed on him, said Dr. Masahiro Katoh, Chairperson, Edogawa NICHE Committee.
In the 2019 Edogawa NICHE Prize Award ceremony at University of Toronto, Canada, Prof Gary Levy, Chair, Awards Committee & Founding Director, CIHR, Transplant program, will honour Dr. Rosenberg with a medal & plaque, whose acceptance speech will be videocasted in NCRM NICHE 2019 in Tokyo, Japan, followed by 2019 Joyce & James Till Travel Grant recipient, PV Sudharsan, a 2012-FCQ elite sharing how FCQ helped in his career (www.j2t2grant.org), and a presentation on Training Program in Regenerative Medicine (www.regenmedcanada.com).
Instituted in 2018, by Jinseisha trust, which owns Edogawa Hospital, Tokyo and Nichi-In Centre for Regenerative Medicine (NCRM), the Edogawa NICHE Prize honours scientists or clinicians whose contributions lead to the development of prevention, diagnosis or treatment of any disease, through an inter-disciplinary interaction. Scholars who attain top scores in the Fujio Cup Quiz since 2006, a part of NCRM NICHE, (www.ncrmniche.org) and gain FCQ Elite status, have a priority to nominate the awardees, which is unique to this prize.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190814005237/en/
Contact information
Queries to:
GN Corporation Co. Ltd.
Samuel Jk Abraham
info@gncorporation.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TVCMALL MWC 2026 -tapahtumassa: johtava mobiilitarvikkeiden tukkukauppa ja älykäs hankinta1.3.2026 08:00:00 EET | Tiedote
MWC Barcelona 2026 korostaa tekoälyn, yhteyksien ja älykkäämpien teknologisten järjestelmien kasvavaa merkitystä, ja samalla mobiilitarvikemarkkinat siirtyvät uuteen vaiheeseen, jota leimaavat nopeus ja monimutkaisuus. Tuotekategoriat laajenevat jatkuvasti, muotoilut ja tyylit päivittyvät yhä nopeammin, ja jälleenmyyjiltä odotetaan reagointia markkinamuutoksiin entistä lyhyemmissä sykleissä. Tuotevalikoiman ajantasaisena pitäminen samalla kun hankintaa hallitaan tehokkaasti on muodostunut todelliseksi haasteeksi jälleenmyyjille ja jakelijoille eri puolilla Eurooppaa. Tämä lehdistötiedote sisältää multimediaa. Katso koko julkaisu täällä: https://www.businesswire.com/news/home/20260121785166/fi/ TVCMALL MWC 2026 -tapahtumassa: johtava mobiilitarvikkeiden tukkukauppa ja älykäs hankinta MWC Barcelona 2026 - Tapahtumassa TVCMALL korostaa rooliaan Euroopan johtavana yhden luukun puhelin tarvikkeita tukkutoimittajana, keskittyen selkeästi siihen, että tukkukauppa ja hankinta olisivat helpompi
TVCMALL at MWC 2026: Leading Mobile Accessories Wholesale and Smarter Sourcing1.3.2026 08:00:00 EET | Press release
As MWC Barcelona 2026 highlights the growing role of AI, connectivity, and smarter technology systems, the mobile accessories market is entering a new phase defined by speed and complexity. Product categories continue to expand, designs and styles update faster, and retailers are expected to respond to market changes in shorter cycles. Keeping product lines up to date while managing sourcing efficiently has become a real challenge for retailers and distributors across Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260121405485/en/ TVCMALL at MWC 2026: Leading Mobile Accessories Wholesale and Smarter Sourcing At MWC Barcelona 2026, TVCMALL highlights its role as a leading one-stop mobile accessories wholesaler in Europe, with a clear focus on making wholesale and sourcing easier, faster, and more reliable. With more than 18 years of experience, TVCMALL works closely with 30+ leading retail partners across Europe, supp
Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE03428.2.2026 02:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that its partner IDEAYA Biosciences, Inc. (“IDEAYA”; Nasdaq: IDYA) has dosed the first patient in IDEAYA’s Phase 1 dose-escalation/expansion clinical trial of IDE034, an investigational B7H3/PTK7 bispecific TOP1 ADC. Pursuant to the companies’ option and license agreement, first patient dosing triggers a $5 million milestone payment to Biocytogen. According to IDEAYA, the Phase 1 study is designed to characterize IDE034’s safety profile, tolerability, and PK as a monotherapy, and IDEAYA also intends to evaluate combination regimens with DNA damage response (DDR) -targeting agents such as its oral PARG inhibitor IDE161 as the program advances. IDE034 is a potential first-in-class bispecific B7H3/PTK7 TOP1 ADC, independently developed by Biocytogen and lice
IQM and Real Asset Acquisition Corp. to Host Conference Call/Webcast to Discuss Proposed Transaction27.2.2026 14:00:00 EET | Press release
IQM Finland Oy, a global leader in full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”), and Real Asset Acquisition Corp. (Nasdaq: RAAQ), a special purpose acquisition company (“RAAQ”), announced that they will host a conference call to discuss their recently announced business combination, including certain transaction highlights. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260227472716/en/ IQM Radiance quantum computer As previously disclosed, on February 23, 2026, IQM and RAAQ announced they have entered into a definitive business combination agreement, which will result in IQM becoming a public company and listing American Depositary Shares on one of the two leading U.S. stock exchanges. The transaction provides funding with the aim to accelerate IQM’s technology and commercial development towards fault-tolerance quantum computing, further advancing its position as a leading p
HighRadius Launches $0 Implementation Fee, $0 Subscription Fee via Outcome Based Pricing for oCFO Software27.2.2026 13:00:00 EET | Press release
HighRadius launches Office of the CFO first Outcome Based Pricing with $0 Implementation fee and $0 Subscription until Go-Live. Customers only pay a fraction of realized gains based on P&L impact. Chapter 1: Outcome Based Pricing (OBP) Introduction of OBP: HighRadius, a provider of 190+ AI agents for Order-to-Cash, Accounts Payable, Record-to-Report, and Treasury introduces Outcome Based Pricing (OBP). Three Components of OBP: Customers pay a) $0 in Implementation fees, b) $0 in Subscription fees until Go Live, c) HighRadius earns a fraction of the actual savings realized by the client. Chapter 2: US GAAP & ASC 606 Constraints Not Designed for Innovation: The traditional ASC 606 model requires companies to standardize and recognize revenue based on contractual obligations. For a traditional SaaS subscription, the obligation is access to software over time. AI agents are designed to deliver quantifiable, real-time Business Outcomes that do not fit the traditional accounting framework. C
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom